

Ethical and economical challenges of using CER & HTA for priority setting in health care

Georg Marckmann


Ludwig-Maximilians-University of Munich, Germany
Institute of Ethics, History & Theory of Medicine


Justice in Modern Health Care – Perspectives for the 21st Century


Bochum, March 28, 2011

Overview

- Background: Why setting limits (“rationing”) is unavoidable...
- Theoretical foundations of just health care: The special moral importance of health
- Procedural criteria: Setting limits fairly...
- Substantive criteria: What services should be included in a basic benefit package?
- Perspective: Utility maximization with fairness constraints – balancing cost-effectiveness with other values
 - Instrument: Cost-conscious guidelines (CCGL)
- Questions & Discussion







Biomedical innovations

Demographic change

Limited financial resources

Demand ↑


+

Supply ↓

Charybdis

Scylla

Scarcity of resources in health care



Increase funding for health care

Increase efficiency („Rationalization“)

Limit services („Rationing“)

Intermediate conclusion (1)

- Efficiency can and should be increased, but not enough to compensate the cost pressure by biomedical innovations and demographic change
- There are convincing ethical (!) arguments to limit public health care spending.
- Setting limits (“rationing”) becomes inevitable
- ⇒ Challenge: setting limits fairly and efficiently!

Rationing in Germany: Empirical evidence

- BMBF-collaborative research project: representative survey 2008 among 1137 German clinicians from intensive medicine & cardiology, 507 answered (45%)
- Item: *During the last 6 months, how often have you withheld a potentially beneficial intervention from a patient for cost reasons or substituted the intervention by a less effective alternative?*

□ Never:	22%	} 78%
□ Less than monthly:	32%	
□ Monthly:	33%	
□ Weekly:	11%	} 13%
□ Daily:	2%	

Strech, D. et al. (2009) Ausmaß und Auswirkungen von Rationierung in deutschen Krankenhäusern. **DMW** 2009;134:1-6.

Just health (care)

- Why is health care special? ⇒ Norman Daniels: “Just health care” (1985)/ “Just health” (2008)
- Function of health care: restore or maintain normal species functioning
- Impairment of normal species functioning through disease and disability restricts an individual’s opportunity
- Health care promotes **equal opportunity** by preventing and curing disease
- Fair equality of opportunity = a requirement of social justice (John Rawls: “Theory of justice” 1971)
- Justice requires universal access to (basic) health care irrespective of ability to pay
- Strong ethical argument for a **regulated universal health care system with equitable financing** (“solidarity”)

Setting limits fairly

Trilemma of ethics:

- (1) Pluralism of ethical theories of justice/just health care
- (2) Limited applicability of most theories
 - Too general to give guidance on concrete allocation decisions
- (3) Health care priorities depend on *substantial conceptions of the good life* ⇔ ideal of neutrality of liberal theories of justice (e.g. Rawls)
 - We cannot infer a concrete hc allocation scheme from an ethical theory of justice or just health care!
 - Fair decision procedures!
(e.g. “accountability of reasonableness” by Daniels & Sabin)

Health priorities and the good life

□ Examples

- Health care for the elderly
- Life extending technologies vs. palliative care
- Intensive care for very low birth weight babies
- Prevention vs. acute care
- Infertility services, organ transplantations

□ Conceptions of the good life determine

- the overall health-care expenditure
- the allocation to different health-care sectors
- the services that are included in a basic benefit package
- what services individual patients demand

Intermediate conclusion (2)

- Ethically legitimate allocation decisions (i.e. setting limits) require
 - (1) Fair decision procedures ⇒
Procedural ethical allocation criteria
 - (2) Good ethical justification ⇒
Substantive ethical allocation criteria

Fair procedures: criteria

- (1) Transparency
- (2) Legitimacy
- (3) Consistency
- (4) Justification based on relevant reasons
- (5) Evidence-based concerning benefits & costs
- (6) Participation of relevant stakeholder groups
- (7) Minimize conflicts of interest
- (8) Revision and appeal mechanisms
- (9) Regulation & control (of these conditions)

cf. Daniels & Sabin, Emanuel, et al.

Fair procedures in practice: examples

- Assessment of interventions (HTA) should be *procedurally* independent of coverage decision
 - E.g. IQWiG vs. G-BA (Federal Joint Commission), NICE vs. DoH
- *Explicit* democratic legitimization for “rationing” bodies
 - Social code book V - sufficient for G-BA??
- Participation of patient representatives in assessment
 - Importance of different outcomes
 - Quality-of-life assessment
- Transparent data basis and rationale of decisions
 - Stakeholders should have opportunity to review the process and comment on decisions

Who should decide? Physicians' opinions

- If in a health care system not all beneficial services can be covered, physicians should decide **case by case** which patient should get which service.
 - 53% (completely agree + somewhat agree)
- If in a health care system not all beneficial services can be covered, it should be regulated **in general rules** (e.g. positive lists, guidelines) „above“ the individual physician-patient relationship, which services are covered by the statutory health care system.
 - 74% (completely agree + somewhat agree)
- Similar ambivalence in the in-depth interviews!

Strech, D. et al. (2009) Ausmaß und Auswirkungen von Rationierung in deutschen Krankenhäusern. **DMW** 2009;134:1-6.

Substantive allocation criteria (1)

- Empirical: Public rationing preferences (e.g. Ubel, Nord)
 - Priority to severely ill patients (even if less cost-effective)
 - No discrimination of people w/ chronic illness / disability
 - Fair distribution of health care services and outcomes
- Political: political deliberative process (N, S, NL...)
- Analytical: Ethical arguments
- ⇒ Most appropriate substantial ethical criteria
 - Individual **medical need** for the treatment
 - severity of disease; urgency of treatment
 - Expected (incremental) **medical benefit** for the patient
 - **Cost-benefit ratio**
 - Meta criterion: *strength of evidence*

Substantive allocation criteria (2)

- Main Challenge: How much weight shall we assign to the different criteria?
 - ⇒ Efficiency-equity trade-off
 - ⇒ Also: Equity-equity trade-off (benefit vs. need)!
 - ⇒ Trade-off cannot be derived from ethical theory
- Ethically most appropriate: exclude services with
 - Small incremental benefit
 - High incremental costs
 - (if more cost-effective alternative available)
- ⇒ **“Utility maximization with fairness constraints”**

Ethical justification

- Justice – *population* perspective
 - Limited resources ⇒ take into account opportunity costs
 - Maximize achievable health gain w/ given resources
 - Consider cost-effectiveness of interventions
- Beneficence – *individual* perspective
 - Minimize the benefit withheld from individual patients
 - Alternative treatment should be available
- ⇒ Obligation to perform CEA & CUA (cf. NICE, IQWiG)
- ⇒ Several methodological challenges, e.g.:
 - ⇒ assess utilities
 - ⇒ distributive consequences of the QALY
 - ⇒ balancing of competing values

Utilities: comparison of methods

Health condition	Rating scale	Standard gamble	Time trade-off
Mild hand pain	0,92	0,91	0,99
Moderate knee pain	0,63	0,83	0,94
Severe headache pain	0,37	0,75	0,90

Source: Ubel P, Pricing life. 2000, 54

QALY – distributive consequences

- Health benefits are maximized with the available resources 😊
- Distribution of benefits does not matter 😞
- Severity of disease is neglected
 - $0,1 \rightarrow 0,2$ is equivalent to $0,8 \rightarrow 0,9$?
 - Undervalues life-saving interventions (cf. Oregon)
- Positive or negative age discrimination?
 - Negative: Age $\uparrow \rightarrow$ possible QALY gain \downarrow
 - Positive: age does not matter
 - 3 QALYs [50 year old] \approx 9 QALYs [70 year old]
- Discrimination of disabled persons
 - Lower gain of QALYs in comparable conditions
- Advantage for common disorders

Methodological options

(1) Quantitative integration

- Incorporate distributional concerns into utility elicitation (e.g. PTO instead of TTO or SG)

(2) Quantitative transformation

- Transform “conventional” QALYs (utilities elicited with TTO, SG) to include other values

(3) Qualitative supplementation


- CEA/CUA based on conventional QALYs
- Add other values informally in fair (political) decision making process (e.g. NICE)

⇒ (Currently) most feasible, justifiable option: (3)

- Validity of quantitative methods still unclear
- More *transparent* (trade-off not hidden in one figure)

Cost-effectiveness plane

Inefficient
 ⇒ ethically
not
 acceptable!



Burden of
 justification
 increases w/ α !
 α big: reject!
 α small: accept!

Difference in
 effectiveness

With small β
 ⇒ ethically
 acceptable!

Efficiency gain
 ⇒ ethically
 mandated!

Cost-effectiveness plane

Ine
 ⇒
 no
 acc

Possible ethical justifications

- Large expected individual benefit
- No alternative intervention available
- High severity of disease
- Innovative character of intervention (potential benefit for future patients)

ffer

Example: lysosomal storage diseases (M. Gaucher, Fabry)

- Very expensive enzyme substitute therapies
- High ICER: >400.000£/QALY
- Without treatment: fatal diseases
- Great individual benefit
- No alternative treatment available

α!
 pt!

Cost ↓
 Effect ↓

Effect ↑

C

III

II

- ↓

With small β
 ⇒ ethically acceptable!

Efficiency gain
 ⇒ ethically mandated!

Cost-conscious guidelines (CCGL)

- Assess effectiveness & cost-effectiveness of medical interventions
- Identify patient subgroups with different incremental benefit & cost-effectiveness
 - ⇒ Exclude subgroups with no additional net-benefit ⇒ efficiency gain
 - ⇒ Exclude subgroups with small incremental benefit & high ICER ⇒ limit services with net-benefit (“rationing”)
 - ⇒ Intervention limited to those patients that benefit most!
- Cf. our collaborative research project
 - BMBF-Forschungsverbund “Allokation”
 - Develop & evaluate CCGL for selected cardiologic interventions: ICD & DES

Example: DES vs. BMS

- Basis: NICE guidance TA152
- Main effect: reduced rate of revascularization with DES vs. BMS (5% vs. 10-25%)
- Mortality: No statistically significant difference

Price difference DES vs. BMS	400€	800€
All patients	98.000 €/QALY	227.000 €/QALY
Pts. w/ long lesion (>15 mm)	62.000 €/QALY	167.000 €/QALY
Pts. w/ small vessel (<3 mm)	33.000 €/QALY	126.000 €/QALY

- Guidance: DES in PCI recommended, if
 - artery has calibre <3mm or lesion longer 15mm *and*
 - price difference between DES & BMS is < 400€

CCGL: Physicians' opinions

- CCGL should limit those interventions that provide **a small incremental benefit** to the patient at **comparably high cost**
 - 92% (completely agree + somewhat agree)

- Physicians should **follow** official CCGLs, which limit the use of interventions that provide only **a small incremental benefit** for the patient at **high costs**
 - 78% (completely agree + somewhat agree)

- To guarantee a **consistent and fair** allocation of scarce resources, physicians **should not deviate** from the recommendations in official CCGLs
 - 30% (completely agree + somewhat agree)

Research & policy implications

- Best feasible, justifiable option at the moment:
 - “Qualitative supplementation” (QALY + informal value judgment) ⇒ fair & open decision making process!!
 - HTA should provide information on other values
- Further research required:
 - Conceptualize equity concerns
 - Further develop & evaluate tools to *quantify* equity concerns
- Comparative evaluation of different decision-making strategies (“policy research”)
 - Assess same set of programs with quantitative transformation vs. qualitative supplementation
 - Compare outcomes with different strategies

Questions for further discussions

- What *ethical criteria* (societal preferences) should be applied in addition to the cost-effectiveness/utility ration?
- How can these criteria be *integrated* into the cost-benefit assessment?
 - qualitative vs. quantitative?
- How can we deal with the "*threshold-problem*"?
 - Balancing cost-effectiveness with other values
- How can we organize a *fair decision procedure* to implement the results of CER & HTA in a health care system?

Biomedical progress

Demographic change

Limited financial resources

Demand ↑


+

Supply ↓

Charybdis

Scylla

Scarcity of resources in health care



Increase funding for health care

Increase efficiency („Rationalization“)

Limit services („Rationing“)

Thank you very much for
your attention!

Contact:
marckmann@lmu.de

Increasing demand for hc

- Biomedical & technological progress
 - Product innovations >> process- & organizational innovations
 - Add-on-technologies >> substitute technologies
- Increasing life expectancy
 - Change of disease spectrum
 - ⇒ chronic & degenerative diseases↑
 - ⇒ multimorbidity↑
 - Increasing demand for long-term care (e.g. Alzheimer's disease)
- Especially: Interaction between technological progress and increasing life expectancy
- "Sisyphus-Syndrome"
 - e.g. Japan: highest life-expectancy + highest cancer mortality
- Increasing demand for health care
- Rising health care expenditures

Limited financial resources

- Declining economic growth
 - High unemployment
 - Decreased tax revenues

- Change in age structure of the population (demographic transition)
 - Life expectancy ↑ + Birth rates ↓ (1.4 in Ge)
 - Aging at the top + aging at the bottom
 - „Double aging“
 - Aging of the population
 - Increasing dependency ratio
(ratio of working age to dependent population)
 - Increasing financial pressure on public hc systems